Lonza Group AG (LZAGF) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Basel, Switzerland. Le PDG actuel est Wolfgang Wienand.
LZAGF a date d'introduction en bourse 2009-02-13, 17,995 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $48.28B.
Lonza Group AG is a global pharmaceutical and biotechnology services company headquartered in Basel, Switzerland, serving customers across Europe, the Americas, Asia, and the Pacific region. Operating through four main segments—Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients—the company provides contract development and manufacturing services for biopharmaceuticals, small molecule drugs, cell and gene therapies, and pharmaceutical ingredients. Its Biologics segment handles drug substance and product manufacturing throughout the product lifecycle, while the Small Molecules segment delivers integrated development and manufacturing for small molecule therapeutics. The Cell & Gene segment specializes in industrializing manufacturing processes for cell therapies, gene therapies, and exosome-based therapies, alongside specialty raw materials and enabling technologies. Founded in 1897, Lonza combines over a century of industry expertise with advanced manufacturing capabilities to support pharmaceutical, biotech, and nutrition markets worldwide.
